Jw Holdings (096760) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jw Holdings (096760) has a cash flow conversion efficiency ratio of 0.118x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩66.90 Billion ≈ $45.34 Million USD) by net assets (₩567.12 Billion ≈ $384.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jw Holdings - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Jw Holdings's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 096760 current and long-term liabilities for a breakdown of total debt and financial obligations.
Jw Holdings Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jw Holdings ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Taiyen Biotech Co Ltd
TW:1737
|
0.028x |
|
Dynamix Corporation III Class A Ordinary Shares
NASDAQ:DNMX
|
9.652x |
|
Bergbahnen Engelberg Truebsee Titlis Bet AG
SW:TIBN
|
0.062x |
|
Maritime Resources Corp.
V:MAE
|
0.038x |
|
RCI Hospitality Holdings Inc
NASDAQ:RICK
|
0.051x |
|
GENFIT S.A. ADR/1 EO-25
F:XUPB
|
N/A |
|
X-Legend Entertainment Co Ltd
TW:4994
|
0.036x |
|
Peninsula Group Ltd
TA:PEN
|
-0.033x |
Annual Cash Flow Conversion Efficiency for Jw Holdings (2007–2024)
The table below shows the annual cash flow conversion efficiency of Jw Holdings from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see Jw Holdings market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩521.39 Billion ≈ $353.34 Million |
₩97.89 Billion ≈ $66.34 Million |
0.188x | -41.70% |
| 2023-12-31 | ₩348.75 Billion ≈ $236.35 Million |
₩112.32 Billion ≈ $76.12 Million |
0.322x | +2.78% |
| 2022-12-31 | ₩333.26 Billion ≈ $225.85 Million |
₩104.43 Billion ≈ $70.77 Million |
0.313x | -12.89% |
| 2021-12-31 | ₩304.82 Billion ≈ $206.57 Million |
₩109.64 Billion ≈ $74.30 Million |
0.360x | +10.92% |
| 2020-12-31 | ₩334.97 Billion ≈ $227.00 Million |
₩108.62 Billion ≈ $73.61 Million |
0.324x | +15.54% |
| 2019-12-31 | ₩351.62 Billion ≈ $238.29 Million |
₩98.68 Billion ≈ $66.88 Million |
0.281x | -42.51% |
| 2018-12-31 | ₩401.00 Billion ≈ $271.75 Million |
₩195.76 Billion ≈ $132.67 Million |
0.488x | +1640.33% |
| 2017-12-31 | ₩374.73 Billion ≈ $253.95 Million |
₩10.51 Billion ≈ $7.12 Million |
0.028x | +126.65% |
| 2016-12-31 | ₩277.59 Billion ≈ $188.12 Million |
₩-29.21 Billion ≈ $-19.80 Million |
-0.105x | -18.65% |
| 2015-12-31 | ₩270.31 Billion ≈ $183.18 Million |
₩-23.98 Billion ≈ $-16.25 Million |
-0.089x | -9.45% |
| 2014-12-31 | ₩211.94 Billion ≈ $143.63 Million |
₩-17.18 Billion ≈ $-11.64 Million |
-0.081x | +64.60% |
| 2013-12-31 | ₩236.03 Billion ≈ $159.95 Million |
₩-54.03 Billion ≈ $-36.62 Million |
-0.229x | -5557.31% |
| 2012-12-31 | ₩205.46 Billion ≈ $139.24 Million |
₩861.85 Million ≈ $584.07K |
0.004x | -89.87% |
| 2010-12-31 | ₩192.45 Billion ≈ $130.42 Million |
₩7.97 Billion ≈ $5.40 Million |
0.041x | +6.94% |
| 2008-12-31 | ₩213.99 Billion ≈ $145.02 Million |
₩8.28 Billion ≈ $5.61 Million |
0.039x | -48.81% |
| 2007-12-31 | ₩214.73 Billion ≈ $145.52 Million |
₩16.24 Billion ≈ $11.01 Million |
0.076x | -- |
About Jw Holdings
JW Holdings Corporation, together with its subsidiaries, operates as a healthcare company in South Korea, the United States, Japan, China, and internationally. The company offers amino acid solutions, gastrointestinal agents, wound care, eye care, liver disease treatment, cold medicine, API, oral and topical analgesic, and other miscellaneous pharmaceutical products. It also offers hairdye, hair … Read more